Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011

Fineline Cube Jan 15, 2026
Company Deals

Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline

Fineline Cube Jan 15, 2026
Company Deals

QYuns’ QX030N Partner Caldera Raises $112.5 Million for IBD Bispecific

Fineline Cube Jan 15, 2026
Company Deals

NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development

Fineline Cube Jan 14, 2026
Company Deals

AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D

Fineline Cube Jan 14, 2026
Policy / Regulatory

NHSA Launches 6th VBP Tender for Medical Consumables in China, Targeting Drug-Coated Balloons

Fineline Cube Jan 13, 2026
Company Drug

J&J’s TECVAYLI Shows 71% PFS Reduction in Phase 3 MajesTEC‑9 for Multiple Myeloma

Fineline Cube Jan 15, 2026
Company Drug

Leads Biolabs’ Opamtistomig Secures FDA Fast Track for EP-NEC as First 4-1BB Bispecific

Fineline Cube Jan 15, 2026
Policy / Regulatory

China’s CDE Launches Pilot Program for Electronic Drug Registration Filings

Fineline Cube Jul 2, 2024

The National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE) in China has issued...

Company Drug

China’s Sichuan Huiyu Pharmaceutical Halts Generic Cytosar Launch Following Strategy Review

Fineline Cube Jul 2, 2024

Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a pharmaceutical company based in China, has announced...

Company Deals

China’s Henlius Biotech Partners with Sermonix for Japan Development of Breast Cancer Drug

Fineline Cube Jul 2, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696), a prominent biopharmaceutical company based in China, has announced...

Company Deals Medical Device

MicroPort Endovascular to Fully Acquire Optimum Medical Device in $65M Deal

Fineline Cube Jul 2, 2024

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a leading Chinese medical technology company, has...

Company Deals

Supercede Therapeutics Partners with Shanghai Universities for Anti-Tumor Cachexia Drug Developmen

Fineline Cube Jul 2, 2024

Fudan University and East China Normal University (ECNU) have entered into a global rights cooperation...

Company Drug

Eisai and Biogen Launch Alzheimer’s Drug Leqembi in China Following Market Approval

Fineline Cube Jul 1, 2024

Eisai Co., Ltd (TYO: 4523), a Japanese pharmaceutical company, in partnership with Biogen Inc. (NASDAQ:...

Company Deals

Healthcare Firms Line Up for HKEX IPOs as Biotech Market Recovery Gains Momentum

Fineline Cube Jul 1, 2024

A number of healthcare companies are seeking to capitalize on the recovering market conditions by...

Company Drug

Hinova Pharmaceuticals’ HP518 Earns FDA Fast-Track Designation for AR+ Triple Negative Breast Cancer

Fineline Cube Jul 1, 2024

Hinova Pharmaceuticals (SHA: 688302), a biopharmaceutical company based in China, has announced that it has...

Company Drug

Jiangsu Hengrui’s Henagliflozin Gains Expanded Indication for Type 2 Diabetes Treatment in China

Fineline Cube Jul 1, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Drug

Gloria Bio’s Motixafortide Approved as Urgently Needed Import Drug by Hainan Medical Products Administration

Fineline Cube Jul 1, 2024

Guangzhou Gloria Biosciences Co., Ltd, a biopharmaceutical company based in China, has received approval from...

Company Deals Digital

Winning Health Partners with Unicom Digitization Medical to Boost Medical Industry Innovation

Fineline Cube Jul 1, 2024

Winning Health (SHE: 300253), a Shanghai-based company in the medical information industry, has entered into...

Company Drug

BeiGene’s Tislelizumab Approved by China’s NMPA for First-Line Extensive Stage Small Cell Lung Cancer

Fineline Cube Jul 1, 2024

BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a biopharmaceutical company, has announced that its programmed-death...

Company Deals

Hisense Medical Teams Up with Tianjin Government and Yujin AI for Intelligent Medical R&D

Fineline Cube Jul 1, 2024

Hisense Medical Equipment Co., Ltd, a leading medical equipment provider based in China, has entered...

Company Drug

Staidson Pharmaceutical’s Bemiltenase Alfa Earns Orphan Drug Designation from US FDA for Hemophilia Treatment

Fineline Cube Jul 1, 2024

Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a biopharmaceutical company based in China, has announced...

Company Deals

Cigna & CMB Life Insurance Partners with Cleveland Clinic Foundation to Enhance Medical Diagnosis for Chinese Patients

Fineline Cube Jul 1, 2024

Cigna & CMB Life Insurance Co., a joint venture between Cigna Corporation, a U.S.-based global...

Company Drug

Grand Pharmaceutical Group Ltd’s SIR-Spheres Set to Reach Wider Patient Base Through MediTrust Health Deal

Fineline Cube Jul 1, 2024

Grand Pharmaceutical Group Ltd (HKG: 0512), a leading pharmaceutical company based in China, has announced...

Company Drug

IASO Biotherapeutics’ RD118 CAR-T Therapy Receives Clinical Trial Approval for Multiple Myeloma

Fineline Cube Jul 1, 2024

IASO Biotherapeutics, a biopharmaceutical company based in China, has announced that it has received tacit...

Company Deals Drug

Yunnan Baiyao Group Secures Global Rights to Kyinno Biotechnology’s Antibody Drug KA-1641

Fineline Cube Jul 1, 2024

Yunnan Baiyao Group Co., Ltd (SHE: 000538), a traditional Chinese medicine (TCM) company based in...

Policy / Regulatory

China’s NHSA Releases 2024 National Reimbursement Drug List Adjustment Plan

Fineline Cube Jul 1, 2024

The National Healthcare Security Administration (NHSA) has published the National Reimbursement Drug List (2024) adjustment...

Company Drug

Henlius Pharmaceutical’s HLX15 Biosimilar Meets Phase I Clinical Endpoints

Fineline Cube Jul 1, 2024

Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced the successful completion of a Phase...

Posts pagination

1 … 281 282 283 … 609

Recent updates

  • J&J’s TECVAYLI Shows 71% PFS Reduction in Phase 3 MajesTEC‑9 for Multiple Myeloma
  • Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011
  • Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline
  • Sunshine Lake Pharma Launches AI-Powered PROTAC Platform to Target Undruggable Proteins
  • QYuns’ QX030N Partner Caldera Raises $112.5 Million for IBD Bispecific
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

J&J’s TECVAYLI Shows 71% PFS Reduction in Phase 3 MajesTEC‑9 for Multiple Myeloma

Company Deals

Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011

Company Deals

Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline

Company Digital

Sunshine Lake Pharma Launches AI-Powered PROTAC Platform to Target Undruggable Proteins

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.